Unapproved drug rejections can no longer hide behind commercial confidentiality.
The FDA's proactive publication of Complete Response Letters is dismantling the industry standard of keeping unapproved drug applications and manufacturing failures private.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
The confidentiality shield around regulatory interactions is dissolving — after CRL publication, even nonpublic FDA records now flow to securities regulators to test corporate claims.
The highly specific manufacturing deficiencies behind the drug's rejection were made publicly available despite historical commercial confidentiality.
The FDA's new rulemaking seeks to formally eliminate the presumption of commercial confidentiality for unapproved drug applications, forcing rejection letters into the public eye.